|Awarded On||November 16, 2016|
|Title||Clinical Evaluation of a Novel T Cell Therapy (BPX-501) for the Treatment of Children and Adults with AML|
|Program||Product Development Research|
|Award Mechanism||Texas Company Product Development Awards|
|Institution/Organization||Bellicum Pharmaceuticals, Inc.|
|Principal Investigator/Program Director||Melissa Aldinger|
Many patients with leukemia are cured by a stem cell transplant after intense chemotherapy. However, cancer relapse, infection, and graft versus host (GvHD) are common in the months after a transplant. The problem is that harmful T cells in the transplant cannot be separated from essential, helpful T cells that kill residual cancer and help stem cells become established. Harmful T cells attack the skin, intestines, and the liver, which they see as foreign. For these reasons, many cancer patients without a matched donor cannot receive a transplant, and those that do risk severe, often fatal complications.
Bellicum Pharmaceuticals has developed a revolutionary new T-cell therapy (BPX-501) t...